INTRODUÇÃO: O objetivo deste estudo é determinar a correlação anatomopatológica das calcificações amorfas agrupadas diagnosticadas na mamografia digital de campo total, ou seja, das calcificações suspeitas mais tênues, uma vez que houve aumento da caracterização de calcificações na mamografia digital. MÉTODOS: Estudo retrospectivo baseado nos laudos mamográficos classificados como categoria BI-RADS 4 no primeiro ano de introdução da técnica digital, com análise dos diagnósticos anatomopatológicos das microcalcificações amorfas agrupadas submetidas à biópsia de fragmento assistida à vácuo no serviço. Calculou-se: os achados anatomopatológicos que se associaram ao achado radiológico de microcalcificações amorfas agrupadas e o valor preditivo positivo destas calcificações biopsiadas. RESULTADOS: Dos 219 achados por microcalcificações amorfas agrupadas, 78 foram submetidos à biópsia de fragmento assistida à vácuo com seguimento conhecido ou cirurgia subsequente. O diagnóstico anatomopatológico correspondeu a oito (10%) casos malignos, 36 (46%) casos benignos, e 34 (44%) diagnósticos de lesões de risco, das quais oito (10%) do subgrupo cicatriz radiada/lesões papilíferas (sete cicatrizes radiadas e um papiloma) e 26 (33%) do subgrupo atipias/ neoplasias lobulares, correspondendo a 14 (18%) hiperplasias ductais atípicas, quatro (5%) neoplasias lobulares e oito (10%) lesões de células colunares com atipia (atipia epitelial plana). A ampliação cirúrgica foi recomendada para as lesões com potencial incerto de malignidade à biópsia e realizada em 65% do subgrupo atipias/neoplasias lobulares, com taxa de subestimação nula (0/18). O tempo médio de seguimento das pacientes com diagnóstico benigno ou de lesão de risco foi 22 meses. CONCLUSÕES: Um terço das microcalcificações amorfas agrupadas em mamografia digital de campo total corresponderam a lesões precursoras representadas pelas atipias (ductais e colunares) e neoplasias lobulares. Essas lesões se associaram às calcificações amorfas agrupadas numa proporção de cerca de 3:1 em relação às lesões malignas, cujo VPP 3 foi 10% / PURPOSE: To determine the anatomopathological correlation of grouped amorphous calcifications (the most tenuous of suspicious calcifications) disclosed on full-field digital mammography, given the enhanced characterization of calcifications provided by digital mammography. METHODS: A retrospective study of mammographic reports classified as BI-RADS® category 4 at a private diagnostic service specialized in breast imaging was carried out on exams performed during the first year of introducing the digital technique. The investigation entailed analysis of the anatomopathological diagnoses of BI-RADS® category 4 for grouped amorphous microcalcifications submitted to vacuum-assisted breast biopsy (VABB). Anatomopathological findings correlated to this radiological finding were determined and positive predictive value of these calcifications submitted to biopsy (PPV 3) was calculated. RESULTS: Of the 219 findings of grouped amorphous microcalcifications, 78 were submitted to VABB with known follow-up or subsequent surgery. The anatomopathological results included eight (10%) malignant cases, 36 (46%) benign cases and 34 (44%) diagnoses of high-risk lesions, eight of which belonged to the radial scar/papillary lesion subgroup (seven radial scars and one papilloma) and 26 (33% of all cases) to the atypia/lobular neoplasia subgroup, comprising 14 atypical ductal hyperplasias, four lobular neoplasias and eight flat epithelial atypia. Extended surgery was recommended for lesions with uncertain malignant potential at biopsy and performed in 65% of the atypia/lobular neoplasia subgroup, with an underestimation rate of zero (0/18). Mean follow-up time of patients diagnosed with benign or high-risk lesions was 22 months. CONCLUSIONS: One-third of grouped amorphous calcifications on full-field digital mammography corresponded to precursory lesions in the form of atypia (ductal and columnar) or lobular neoplasias. These lesions were associated to grouped amorphous calcifications at a ratio of 3:1 compared to malignant lesions,whose PPV 3 was 10%

INTRODUÇÃO: O objetivo deste estudo é determinar a correlação anatomopatológica das calcificações amorfas agrupadas diagnosticadas na mamografia digital de campo total, ou seja, das calcificações suspeitas mais tênues, uma vez que houve aumento da caracterização de calcificações na mamografia digital. MÉTODOS: Estudo retrospectivo baseado nos laudos mamográficos classificados como categoria BI-RADS 4 no primeiro ano de introdução da técnica digital, com análise dos diagnósticos anatomopatológicos das microcalcificações amorfas agrupadas submetidas à biópsia de fragmento assistida à vácuo no serviço. Calculou-se: os achados anatomopatológicos que se associaram ao achado radiológico de microcalcificações amorfas agrupadas e o valor preditivo positivo destas calcificações biopsiadas. RESULTADOS: Dos 219 achados por microcalcificações amorfas agrupadas, 78 foram submetidos à biópsia de fragmento assistida à vácuo com seguimento conhecido ou cirurgia subsequente. O diagnóstico anatomopatológico correspondeu a oito (10%) casos malignos, 36 (46%) casos benignos, e 34 (44%) diagnósticos de lesões de risco, das quais oito (10%) do subgrupo cicatriz radiada/lesões papilíferas (sete cicatrizes radiadas e um papiloma) e 26 (33%) do subgrupo atipias/ neoplasias lobulares, correspondendo a 14 (18%) hiperplasias ductais atípicas, quatro (5%) neoplasias lobulares e oito (10%) lesões de células colunares com atipia (atipia epitelial plana). A ampliação cirúrgica foi recomendada para as lesões com potencial incerto de malignidade à biópsia e realizada em 65% do subgrupo atipias/neoplasias lobulares, com taxa de subestimação nula (0/18). O tempo médio de seguimento das pacientes com diagnóstico benigno ou de lesão de risco foi 22 meses. CONCLUSÕES: Um terço das microcalcificações amorfas agrupadas em mamografia digital de campo total corresponderam a lesões precursoras representadas pelas atipias (ductais e colunares) e neoplasias lobulares. Essas lesões se associaram às calcificações amorfas agrupadas numa proporção de cerca de 3:1 em relação às lesões malignas, cujo VPP 3 foi 10% / PURPOSE: To determine the anatomopathological correlation of grouped amorphous calcifications (the most tenuous of suspicious calcifications) disclosed on full-field digital mammography, given the enhanced characterization of calcifications provided by digital mammography. METHODS: A retrospective study of mammographic reports classified as BI-RADS® category 4 at a private diagnostic service specialized in breast imaging was carried out on exams performed during the first year of introducing the digital technique. The investigation entailed analysis of the anatomopathological diagnoses of BI-RADS® category 4 for grouped amorphous microcalcifications submitted to vacuum-assisted breast biopsy (VABB). Anatomopathological findings correlated to this radiological finding were determined and positive predictive value of these calcifications submitted to biopsy (PPV 3) was calculated. RESULTS: Of the 219 findings of grouped amorphous microcalcifications, 78 were submitted to VABB with known follow-up or subsequent surgery. The anatomopathological results included eight (10%) malignant cases, 36 (46%) benign cases and 34 (44%) diagnoses of high-risk lesions, eight of which belonged to the radial scar/papillary lesion subgroup (seven radial scars and one papilloma) and 26 (33% of all cases) to the atypia/lobular neoplasia subgroup, comprising 14 atypical ductal hyperplasias, four lobular neoplasias and eight flat epithelial atypia. Extended surgery was recommended for lesions with uncertain malignant potential at biopsy and performed in 65% of the atypia/lobular neoplasia subgroup, with an underestimation rate of zero (0/18). Mean follow-up time of patients diagnosed with benign or high-risk lesions was 22 months. CONCLUSIONS: One-third of grouped amorphous calcifications on full-field digital mammography corresponded to precursory lesions in the form of atypia (ductal and columnar) or lobular neoplasias. These lesions were associated to grouped amorphous calcifications at a ratio of 3:1 compared to malignant lesions,whose PPV 3 was 10%

INTRODUCTION: Patients with primary hyperparathyroidism generally have a single parathyroid adenoma that causes excessive excretion of parathyroid hormone. For about 2% to 15% of these patients, a double adenoma is present that involves one lesion on each side of the neck. CASE PRESENTATION: We describe a case of double parathyroid adenoma causing asymptomatic hypercalcemia. A presurgical technetium99m (Tc99m) sestamibi scan suggested an ipsilateral double adenoma in the left thyroid lobe. An intraoperative parathyroid hormone assay confirmed its successful removal. DISCUSSION: Although double adenomas are not yet widely acknowledged, presurgical imaging and nuclear scans can help to localize multiple lesions, and intraoperative parathyroid hormone assays can confirm the diagnosis and cure.

<p>Uvod: Implementacija brojnih neuroradiolo&scaron;kih modaliteta je značajno uticala na način i efikasnost sprovođenja dijagnostike tumora mozga. Na osnovu neinvazivno dobijenih podataka može se postaviti diferencijalna dijagnoza, ali do sada nije potvrđena nijedna neuroradiolo&scaron;ka metoda koja može samostalno i konačno da postavi definitivnu patohistolo&scaron;ku (PH) dijagnozu. Stereotaksična biopsija je neurohirur&scaron;ka procedura kojom se, bez bitnog naru&scaron;avanja integriteta i funkcije moždanog tkiva, može obezbediti reprezentativni uzorak intrakranijalne tumorske promene radi sprovođenja PH i drugih specifičnih analiza, u cilju postavljanja tačne dijagnoze i potom primene adekvatnog lečenja. Cilj: Cilj ove studije je da se utvrditi mogućnost uzorkovanja reprezentativnog tkiva za postavljanje PH dijagnoze uz pomoć stereotaksične biopsije kod pacijenata sa tumorom mozga, kao i da se utvrdi vrsta i učestalost eventualnih komplikacija same procedure i postojanje korelacije između PH nalaza dobijenog stereotaksičnom biopsijom i rezultata sprovedenih neuroradiolo&scaron;kih ispitivanja. Materijal i metode: Sprovedeno istraživanje je bilo kliničko, prospektivno, a uzorak je činilo ukupno 50 pacijenata koji su bili hospitalizovani na Klinici za neurohirurgiju KCV zbog dijagnostikovane tumorske promene mozga i postavljene indikacije za stereotaksičnu biopsiju, u periodu od septembra 2016. godine do januara 2018. godine. Svi pacijenti koji su uključeni u studiju su u sklopu sprovedene dijagnostičke obrade imali načinjen magnetno rezonanantni (MRI) pregled glave na osnovu kojeg su se određivale morfolo&scaron;ke karakteristike tumora i vr&scaron;ila procena prirode tumorske promene mozga, a kod ukupno 25 pacijenata je dodatno načinjena MR spektroskopija (MRS) dijagnostikovane tumorske promene sa ciljem određivanja biohemijskog profila i dodatne procene i karakterizacije tkiva. Nakon sprovedene detaljne onkolo&scaron;ke obrade i adekvatne pripreme, se sprovodila kompjuterizovanom tomografijom (CT) navođena stereotaksična biopsija sa ramom u cilju uzorkovanja adekvatnog tkiva za PH analizu. U toku istraživanja procena uspe&scaron;nosti uzorkovanja reprezentativnog tkiva se vr&scaron;ila pregledom bioptata od strane patologa, a nakon procedure se kliničkim pregledom i kontrolnim CT pregledom glave utvrđivao stepen komplikacija. Rezultati: Dobijeni rezultati su pokazali da su fokalni neurolo&scaron;ki deficit i moždani sindrom bili najče&scaron;ći klinički simptomi i znaci kod pacijenata kod kojih je indikovana stereotaksična biopsija tumora mozga. Prema MRI nalazu najzastupljenije su bile difuzne tumorske promene sa 36% udela u uzorku, zatim solitarne sa 34% i multifokalne sa 20%, a potom multicentrične tumorske promene koje su predstavljale 10% uzorka. Takođe, na osnovu MRI i MRS nalaza je oko 80% tumora procenjeno kao najverovatnije glijalnog porekla. U 95,9% slučaja je postavljena precizna PH dijagnoza. Nepromenjeno stanje svesti i neurolo&scaron;ki nalaz su imali 92% pacijenata nakon biopsije, a kod 3 pacijenta (6%) je do&scaron;lo do razvoja prolaznog neurolo&scaron;kog deficita, dok je jedan pacijent (2%) razvio trajan neurolo&scaron;ki deficit. Ukupan morbiditet vezan za proceduru je stoga 2%, a nije zabeležen ni jedan smrtni slučaj (mortalitet 0%) tokom sprovođenja studije. Zaključak: Stereotaksična biopsija je dokazana i veoma pouzdana procedura sa malim brojem komplikacija i niskom stopom morbiditeta i mortaliteta, kojom se omogućava dobijanje reprezentativnog uzorka tumorskog tkiva za postavljanje sigurne patohistolo&scaron;ke dijagnoze. Intraoperativna PH analiza dela uzorka tkiva dodatno pobolj&scaron;ava uspe&scaron;nost pri uzorkovanju i postavljanju definitivne PH dijagnoze. Savremene neuroradiolo&scaron;ke metode imaju visoku specifičnost u razlikovanju biolo&scaron;ke prirode tumorskih promena, ali se ne mogu koristi nezavisno od PH analize uzorka tkiva</p> / <p><!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <w:PunctuationKerning/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> <w:DontGrowAutofit/> <w:SplitPgBreakAndParaMark/> <w:DontVertAlignCellWithSp/> <w:DontBreakConstrainedForcedTables/> <w:DontVertAlignInTxbx/> <w:Word11KerningPairs/> <w:CachedColBalance/> </w:Compatibility> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="&#45;-"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument></xml><![endif]--><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="0" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles></xml><![endif]--><!--[if gte mso 10]><style> /* Style Definitions */ table.MsoNormalTable{mso-style-name:"Table Normal";mso-tstyle-rowband-size:0;mso-tstyle-colband-size:0;mso-style-noshow:yes;mso-style-priority:99;mso-style-qformat:yes;mso-style-parent:"";mso-padding-alt:0in 5.4pt 0in 5.4pt;mso-para-margin-top:0in;mso-para-margin-right:0in;mso-para-margin-bottom:10.0pt;mso-para-margin-left:0in;line-height:115%;mso-pagination:widow-orphan;font-size:11.0pt;font-family:"Calibri","sans-serif";mso-ascii-font-family:Calibri;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:minor-bidi;}</style><![endif]-->Introduction: The implementation of numerous neuroradiological techniques has significantly influenced the way and the efficiency in which the diagnosis of brain tumor is established. Based on non-invasive imaging data, a differential diagnosis can be made, but no neuroradiological method has been established so far, which can finally make a definitive diagnosis. Stereotactic biopsy is a neurosurgical procedure that can provide a representative sample of any intracranial tumor in order to performe histopathological and other specific examinations, and to set the exact diagnosis and then apply adequate treatment, but without significantly impairing the integrity and function of brain tissue. Objective: The aim of this study is to determine the diagnostic value of stereotactic biopsy and ability of providing the representative tissue in order to establish a pathohistological diagnosis in patients with brain tumors. Also, the aim is to determine the type and frequency of possible complications of the procedure itself and the correlation between the pathohistological findings obtained and the results of the conducted neuroradiological examinations. Materials and methods: This research was clinical, prospective and included a total of 50 patients who were hospitalized at the Clinical Center of Vojvodina, from September 2016 to January 2018, due to diagnosed brain tumor for which the stereotactic biopsy is indicated. In all patients magnetic resonance (MRI) examination of the head was used to determine morphological characteristics and assesse the nature of the brain tumor tissue, and in a total of 25 patients MR spectroscopy was additionally made with the goal of determining the biochemical profile and additional tissue assessment and characterization. After detailed oncological assessment, completed laboratory and radiological diagnostics, a CT guided framebased stereotactic biopsy was performed for the purpose of sampling tumor tissue for pathohistological analysis. During the research, the success rate of biopsy in providing the representative tissue and establishing the diagnosis was performed by a pathologist, and after the procedure, a clinical and a control head CT examination was used to review the rate of complications. Results: The results obtained showed that focal neurological deficit and psychoorganic syndrome were the most common clinical symptoms and signs in this study. According to MRI, the most common were diffuse brain tumors with 36% of the sample, then solitary with 34% and multifocal with 20%, followed by multicentric tumors representing 10% of the study sample. Also, based on MRI and MRS findings, approximately 80% of tumors are estimated to be most likely of glial origin. In 95.9% of cases, a complete pathohistological (PH) diagnosis was established. The unchanged neurological status was observed in 92% of patients after biopsy, and 3 patients (6%) developed a transient neurological deficit, while only one patient (2%) developed a permanent neurological deficit. The total morbidity associated with the procedure is therefore 2%, and no deaths (mortality 0%) related to the procedure during the study is recorded. Conclusion: Stereotactic biopsy is highly reliable procedure with a small number of complications and a low morbidity and mortality rate, which allows us to acquire the representative sample of brain tumor tissue and to establish a pathohistological diagnosis. Intraoperative PH analysis of acquired tissue samples further enhances the sampling performance and the setting of definitive PH diagnosis. Modern neuroradiological modalities have a high specificity in distinguishing the biological nature of brain tumors, but they still can not be used independently of the pathohistological analysis of the tissue sample.</p>

Introdução: Pacientes portadores de câncer estão sobrevivendo mais devido aos avanços no diagnóstico precoce e tratamento dos tumores. A diminuição da mortalidade relacionada ao câncer e o envelhecimento da população acarretaram um número crescente de pacientes oncológicos internados em UTI. Objetivos: Identificar a prevalência e os fatores de risco para IRA nos pacientes oncológicos críticos. Métodos: Foram avaliados, prospectivamente, 371 pacientes oncológicos internados nas UTIs do Instituto do Câncer do Estado de São Paulo e do Hospital AC Camargo, entre novembro de 2011 a março de 2013. Os pacientes foram avaliados na admissão, 24h e 48h da internação na UTI. Foram coletados os parâmetros demográficos, clínicos e laboratoriais os quais foram analisados para os desfechos IRA, conforme o critério AKIN (Cr > 0,3 mg/dl ou aumento de 50% sobre a Cr basal em 48h) e óbito na UTI. Os dados foram submetidos à análise bivariada e multivariada. Resultados: A incidência de IRA nos pacientes oncológicos foi de 45,1%, sendo que apenas 5,2% necessitaram de tratamento dialítico. Os pacientes com IRA apresentaram mais frequentemente admissão cirúrgica (49% IRA vs 34% sem IRA; p=0,022). Na admissão à UTI, os fatores associados ao desenvolvimento de IRA (IRA vs sem IRA) foram: ventilação mecânica (26,6% vs 16,0%; p=0,031), frequência cardíaca (88 bpm vs 82 bpm; p=0,029), balanço hídrico (575 ml vs 275 ml; p = 0,0002), lactato (19 mg/dL vs 17 mg/dL; p= 0,046) e fósforo (3,9 mg/dL vs 3,4 mg/dL; p < 0,0001). A taxa de óbito hospitalar foi de 37,3% sendo que 25,3% ocorreu na UTI. A mortalidade foi mais prevalente em pacientes com câncer hematológico (8,6% sobreviventes vs 19,5% óbitos; p = 0,008), procedentes do pronto atendimento (23,5% sobreviventes vs 34,1% óbitos; p = 0,002), admissão clínica (50,4% sobreviventes vs 84,1% óbitos; p < 0,0001) e internação não planejada (59,9% vs 86,6% óbitos; p < 0,0001). Outros fatores relacionados ao óbito foram: sinais de congestão, uso de drogas vasoativas, choque séptico e infecção respiratória (p < 0,0001). Os dias de internação prévios à admissão na UTI também se relacionaram ao óbito (6 dias óbitos vs 2 dias sobreviventes; p < 0,0001). Os exames laboratoriais que se relacionaram ao óbito foram (sobreviventes vs óbitos): hipoalbuminemia (2,7 g/dL vs 2,4 g/dL; p= 0,003), aumento do INR (1,3 vs 1,5; p < 0,0001); aumento do lactato (17 mg/dL vs 20,5 mg/dL; p = 0,037), PCR (41,8 mg/dL vs 148,4 mg/dL; p < 0,0001) e TP (69% vs 59,5%; p = 0,001). Conclusão: A IRA é frequente em pacientes oncológicos admitidos na UTI e apresenta alta mortalidade. As ocorrências de IRA e óbito encontram-se mais relacionados com a gravidade das disfunções orgânicas no momento da admissão à UTI, do que às características da neoplasia de base / Introduction: Cancer patients are currently presenting longer survival due to advances in diagnosis and treatment. Mortality reduction related to cancer and aging of population had led to an increased admission of cancer patients in the ICU. Objectives: Evaluation of the prevalence and risk factors for AKI in critically ill cancer patients. Methods: It was prospectively evaluated 371 cancer patients admitted to the ICU in Instituto do Câncer do Estado de São Paulo and Hospital AC Camargo, from November 2011 until March 2013. Patients were evaluated at admission, 24h and 48h in the ICU. Demographic, clinical and laboratory parameters were collected which were correlated with the outcome AKI (AKIN I - Cr > 0.3 mg/dL or 50% increase over baseline in 48h) and mortality in the ICU. Statistical analysis was performed using bivariate and multivariate analysis. Results: The incidence of AKI in cancer patients was 45.1% but only 5.2% were dialysed. AKI patients were more frequently admitted due to surgical admission (AKI 53% vs. 49% non-AKI, p=0.022). At ICU admission, factors associated with AKI development (AKI vs. non-AKI) were: mechanical ventilation (26.6% vs. 16%, p =0.031), heart beats (88 bpm vs. 82 bpm, p=0.029), fluid balance (575 ml vs. 275 ml, p=0.0002), lactate (19 mg/dLvs. 17 mg/dL, p=0.046) and phosphorus (3.9 mg/dL vs. 3.4 mg/dL, p < 0.0001). Hospital mortality rate was 37.3% whereas ICU mortality was 25.3%. Mortality was more prevalent in patients with hematological cancer (8.6% survivors vs. 19.5% non-survivors, p = 0.008), patients from emergency room (23.5% survivors vs. 34.1% non-survivors, p = 0.002), patients with clinical admission (50.4% survivors vs. 84.1% non-survivors, p < 0.0001) and non-elective admission (59.9% vs. 86.6% non-survivors, p < 0.0001). Other factors related to mortality were: volume overload, vasoactive drugs use, septic shock and pulmonary infection (p < 0.0001). Hospitalization period before ICU admission also correlated with mortality (6 days survivors vs. 2 days non-survivors, p 0.0001). The laboratory parameters that correlated to mortality were (survivors vs. non-survivors): hypoalbuminemia (2.7 g/dL vs. 2.4 g/dL, p=0.003), increased INR (1.3 vs. 1.5, p < 0.0001), increased lactate (17 mg/dL vs. 20.5 mg/dL, p=0.037), PCR (41.8 mg/dL vs 148.4 mg/dL, p < 0.0001) e PT (69% vs. 59.5%, p = 0.001). Conclusions: AKI is a frequent complication in cancer patients admitted to ICU, presenting high mortality rate. AKI and mortality outcomes are more related to the severity of organs dysfunction at ICU admission than the patient´s cancer disease

Introdução: Pacientes portadores de câncer estão sobrevivendo mais devido aos avanços no diagnóstico precoce e tratamento dos tumores. A diminuição da mortalidade relacionada ao câncer e o envelhecimento da população acarretaram um número crescente de pacientes oncológicos internados em UTI. Objetivos: Identificar a prevalência e os fatores de risco para IRA nos pacientes oncológicos críticos. Métodos: Foram avaliados, prospectivamente, 371 pacientes oncológicos internados nas UTIs do Instituto do Câncer do Estado de São Paulo e do Hospital AC Camargo, entre novembro de 2011 a março de 2013. Os pacientes foram avaliados na admissão, 24h e 48h da internação na UTI. Foram coletados os parâmetros demográficos, clínicos e laboratoriais os quais foram analisados para os desfechos IRA, conforme o critério AKIN (Cr > 0,3 mg/dl ou aumento de 50% sobre a Cr basal em 48h) e óbito na UTI. Os dados foram submetidos à análise bivariada e multivariada. Resultados: A incidência de IRA nos pacientes oncológicos foi de 45,1%, sendo que apenas 5,2% necessitaram de tratamento dialítico. Os pacientes com IRA apresentaram mais frequentemente admissão cirúrgica (49% IRA vs 34% sem IRA; p=0,022). Na admissão à UTI, os fatores associados ao desenvolvimento de IRA (IRA vs sem IRA) foram: ventilação mecânica (26,6% vs 16,0%; p=0,031), frequência cardíaca (88 bpm vs 82 bpm; p=0,029), balanço hídrico (575 ml vs 275 ml; p = 0,0002), lactato (19 mg/dL vs 17 mg/dL; p= 0,046) e fósforo (3,9 mg/dL vs 3,4 mg/dL; p < 0,0001). A taxa de óbito hospitalar foi de 37,3% sendo que 25,3% ocorreu na UTI. A mortalidade foi mais prevalente em pacientes com câncer hematológico (8,6% sobreviventes vs 19,5% óbitos; p = 0,008), procedentes do pronto atendimento (23,5% sobreviventes vs 34,1% óbitos; p = 0,002), admissão clínica (50,4% sobreviventes vs 84,1% óbitos; p < 0,0001) e internação não planejada (59,9% vs 86,6% óbitos; p < 0,0001). Outros fatores relacionados ao óbito foram: sinais de congestão, uso de drogas vasoativas, choque séptico e infecção respiratória (p < 0,0001). Os dias de internação prévios à admissão na UTI também se relacionaram ao óbito (6 dias óbitos vs 2 dias sobreviventes; p < 0,0001). Os exames laboratoriais que se relacionaram ao óbito foram (sobreviventes vs óbitos): hipoalbuminemia (2,7 g/dL vs 2,4 g/dL; p= 0,003), aumento do INR (1,3 vs 1,5; p < 0,0001); aumento do lactato (17 mg/dL vs 20,5 mg/dL; p = 0,037), PCR (41,8 mg/dL vs 148,4 mg/dL; p < 0,0001) e TP (69% vs 59,5%; p = 0,001). Conclusão: A IRA é frequente em pacientes oncológicos admitidos na UTI e apresenta alta mortalidade. As ocorrências de IRA e óbito encontram-se mais relacionados com a gravidade das disfunções orgânicas no momento da admissão à UTI, do que às características da neoplasia de base / Introduction: Cancer patients are currently presenting longer survival due to advances in diagnosis and treatment. Mortality reduction related to cancer and aging of population had led to an increased admission of cancer patients in the ICU. Objectives: Evaluation of the prevalence and risk factors for AKI in critically ill cancer patients. Methods: It was prospectively evaluated 371 cancer patients admitted to the ICU in Instituto do Câncer do Estado de São Paulo and Hospital AC Camargo, from November 2011 until March 2013. Patients were evaluated at admission, 24h and 48h in the ICU. Demographic, clinical and laboratory parameters were collected which were correlated with the outcome AKI (AKIN I - Cr > 0.3 mg/dL or 50% increase over baseline in 48h) and mortality in the ICU. Statistical analysis was performed using bivariate and multivariate analysis. Results: The incidence of AKI in cancer patients was 45.1% but only 5.2% were dialysed. AKI patients were more frequently admitted due to surgical admission (AKI 53% vs. 49% non-AKI, p=0.022). At ICU admission, factors associated with AKI development (AKI vs. non-AKI) were: mechanical ventilation (26.6% vs. 16%, p =0.031), heart beats (88 bpm vs. 82 bpm, p=0.029), fluid balance (575 ml vs. 275 ml, p=0.0002), lactate (19 mg/dLvs. 17 mg/dL, p=0.046) and phosphorus (3.9 mg/dL vs. 3.4 mg/dL, p < 0.0001). Hospital mortality rate was 37.3% whereas ICU mortality was 25.3%. Mortality was more prevalent in patients with hematological cancer (8.6% survivors vs. 19.5% non-survivors, p = 0.008), patients from emergency room (23.5% survivors vs. 34.1% non-survivors, p = 0.002), patients with clinical admission (50.4% survivors vs. 84.1% non-survivors, p < 0.0001) and non-elective admission (59.9% vs. 86.6% non-survivors, p < 0.0001). Other factors related to mortality were: volume overload, vasoactive drugs use, septic shock and pulmonary infection (p < 0.0001). Hospitalization period before ICU admission also correlated with mortality (6 days survivors vs. 2 days non-survivors, p 0.0001). The laboratory parameters that correlated to mortality were (survivors vs. non-survivors): hypoalbuminemia (2.7 g/dL vs. 2.4 g/dL, p=0.003), increased INR (1.3 vs. 1.5, p < 0.0001), increased lactate (17 mg/dL vs. 20.5 mg/dL, p=0.037), PCR (41.8 mg/dL vs 148.4 mg/dL, p < 0.0001) e PT (69% vs. 59.5%, p = 0.001). Conclusions: AKI is a frequent complication in cancer patients admitted to ICU, presenting high mortality rate. AKI and mortality outcomes are more related to the severity of organs dysfunction at ICU admission than the patient´s cancer disease